{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:29:56Z","timestamp":1793330996922,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s00520-010-0821-1","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T18:50:33Z","timestamp":1266951033000},"page":"333-341","source":"Crossref","is-referenced-by-count":70,"title":["Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer"],"prefix":"10.1007","volume":"19","author":[{"given":"Wylie","family":"Hosmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Malin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,24]]},"reference":[{"key":"821_CR1","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258\u20132266","journal-title":"Cancer"},{"key":"821_CR2","first-page":"432","volume":"98","author":"JHJ Glaspy","year":"2001","unstructured":"Glaspy JHJ, Flyer R et al (2001) Febrile Neutropenia is associated with an increase in the incidence, duration, and severity of chemotherapy toxicities. Blood 98:432","journal-title":"Blood"},{"key":"821_CR3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.1992.10.2.316","volume":"10","author":"J Talcott","year":"1992","unstructured":"Talcott J, Siegel R, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316\u2013322","journal-title":"J Clin Oncol"},{"key":"821_CR4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164\u2013170","journal-title":"N Engl J Med"},{"key":"821_CR5","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158\u20133167","journal-title":"J Clin Oncol"},{"key":"821_CR6","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205","journal-title":"J Clin Oncol"},{"key":"821_CR7","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.1996.14.2.636","volume":"14","author":"JY Blay","year":"1996","unstructured":"Blay JY, Chauvin F, Le Cesne A et al (1996) Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 14:636\u2013643","journal-title":"J Clin Oncol"},{"key":"821_CR8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bjc.6600724","volume":"88","author":"I Ray-Coquard","year":"2003","unstructured":"Ray-Coquard I, Borg C, Bachelot T et al (2003) Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 88:181\u2013186","journal-title":"Br J Cancer"},{"key":"821_CR9","first-page":"IV-55-61","volume":"40","author":"JL Warren","year":"2002","unstructured":"Warren JL, Harlan LC, Fahey A et al (2002) Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40:IV-55-61","journal-title":"Med Care"},{"key":"821_CR10","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1002\/1097-0142(19951201)76:11<2343::AID-CNCR2820761124>3.0.CO;2-#","volume":"76","author":"C Zippin","year":"1995","unstructured":"Zippin C, Lum D, Hankey BF (1995) Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 76:2343\u20132350","journal-title":"Cancer"},{"key":"821_CR11","first-page":"87","volume":"5","author":"C Zippin","year":"1993","unstructured":"Zippin C, Lum D (1993) Study of completeness of the surveillance, epidemiology and end results (SEER) program case ascertainment by hospital size and casefinding source. Health Rep 5:87\u201390","journal-title":"Health Rep"},{"key":"821_CR12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0895-4356(99)00011-6","volume":"52","author":"X Du","year":"1999","unstructured":"Du X, Freeman JL, Goodwin JS (1999) Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. Surveillance, epidemiology and end results. J Clin Epidemiol 52:463\u2013470","journal-title":"J Clin Epidemiol"},{"key":"821_CR13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00005650-200203000-00004","volume":"40","author":"EB Lamont","year":"2002","unstructured":"Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA (2002) Construct validity of Medicare chemotherapy claims: the case of 5FU. Med Care 40:201\u2013211","journal-title":"Med Care"},{"key":"821_CR14","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/1097-0142(20010815)92:4<730::AID-CNCR1376>3.0.CO;2-P","volume":"92","author":"X Du","year":"2001","unstructured":"Du X, Goodwin JS (2001) Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer 92:730\u2013737","journal-title":"Cancer"},{"key":"821_CR15","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.260.15.2253","volume":"260","author":"S Greenfield","year":"1988","unstructured":"Greenfield S, Aronow HU, Elashoff RM, Watanabe D (1988) Flaws in mortality data. The hazards of ignoring comorbid disease. Jama 260:2253\u20132255","journal-title":"Jama"},{"key":"821_CR16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archinte.156.1.85","volume":"156","author":"CJ Newschaffer","year":"1996","unstructured":"Newschaffer CJ, Penberthy L, Desch CE et al (1996) The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 156:85\u201390","journal-title":"Arch Intern Med"},{"key":"821_CR17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-120-2-199401150-00002","volume":"120","author":"WA Satariano","year":"1994","unstructured":"Satariano WA, Ragland DR (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104\u2013110","journal-title":"Ann Intern Med"},{"key":"821_CR18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"821_CR19","doi-asserted-by":"crossref","first-page":"IV-26-35","DOI":"10.1097\/00005650-200208001-00004","volume":"40","author":"CN Klabunde","year":"2002","unstructured":"Klabunde CN, Warren JL, Legler JM (2002) Assessing comorbidity using claims data: an overview. Med Care 40:IV-26-35","journal-title":"Med Care"},{"key":"821_CR20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613\u2013619","journal-title":"J Clin Epidemiol"},{"key":"821_CR21","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","volume":"53","author":"CN Klabunde","year":"2000","unstructured":"Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258\u20131267","journal-title":"J Clin Epidemiol"},{"key":"821_CR22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","volume":"10","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427\u2013437","journal-title":"Oncologist"},{"key":"821_CR23","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.1998.16.6.2065","volume":"16","author":"H Gomez","year":"1998","unstructured":"Gomez H, Hidalgo M, Casanova L et al (1998) Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol 16:2065\u20132069","journal-title":"J Clin Oncol"},{"key":"821_CR24","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1080\/1042819031000119262","volume":"44","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Morrison VA, Dale DC et al (2003) Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 44:2069\u20132076","journal-title":"Leuk Lymphoma"},{"key":"821_CR25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM198509263131306","volume":"313","author":"JH Wasson","year":"1985","unstructured":"Wasson JH, Sox HC, Neff RK, Goldman L (1985) Prediction rules. Applications and methodological standards. N Engl J Med 313:793\u2013799","journal-title":"N Engl J Med"},{"key":"821_CR26","volume-title":"Medical decision making","author":"HC Sox","year":"1988","unstructured":"Sox HC, Blatt MA, Higgins MC, Marton HI (1988) Medical decision making. Buttersworth Publishing, Boston, MA"},{"key":"821_CR27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361\u2013387","journal-title":"Stat Med"},{"key":"821_CR28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3816\/CLM.2001.n.011","volume":"2","author":"VA Morrison","year":"2001","unstructured":"Morrison VA, Picozzi V, Scott S et al (2001) The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2:47\u201356","journal-title":"Clin Lymphoma"},{"key":"821_CR29","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","volume":"22","author":"GH Lyman","year":"2004","unstructured":"Lyman GH, Dale DC, Friedberg J et al (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 22:4302\u20134311","journal-title":"J Clin Oncol"},{"key":"821_CR30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","volume":"6","author":"J Crawford","year":"2008","unstructured":"Crawford J, Dale DC, Kuderer NM et al (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6:109\u2013118","journal-title":"J Natl Compr Canc Netw"},{"key":"821_CR31","doi-asserted-by":"crossref","first-page":"759s","DOI":"10.1200\/JCO.2005.02.155","volume":"23","author":"G Lyman","year":"2005","unstructured":"Lyman G, Crawford J, Wolff D et al (2005) A risk model for first cycle of febrile neutropenia in cancer patients receiving systemic chemotherapy. J Clin Oncol 23:759s","journal-title":"J Clin Oncol"},{"key":"821_CR32","doi-asserted-by":"crossref","first-page":"666","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00048","volume":"127","author":"LI Iezzoni","year":"1997","unstructured":"Iezzoni LI (1997) Assessing quality using administrative data. Ann Intern Med 127:666\u2013674","journal-title":"Ann Intern Med"},{"key":"821_CR33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10552-005-0502-4","volume":"17","author":"S Chen-Hardee","year":"2006","unstructured":"Chen-Hardee S, Chrischilles EA, Voelker MD et al (2006) Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control 17:647\u2013654","journal-title":"Cancer Causes Control"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00520-010-0821-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T09:20:27Z","timestamp":1558862427000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-010-0821-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,24]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1007\/s00520-010-0821-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,24]]}}}